Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01875 TOT BIOPHARM-B
RTNominal up1.550 +0.030 (+1.974%)
Others

03/01/2022 15:13

TOT BIOPHARM (01875) to build research & development centre

[ET Net News Agency, 3 January 2022] TOT BIOPHARM International Company Limited (01875)
said TOT Suzhou (a wholly-owned subsidiary of the company) entered into the construction
agreement with Shanghai Baoye for the construction of the Global Research and Development
Centre at the group's headquarters in Suzhou Industrial Park, Suzhou, Jiangsu Province,
the PRC, with the contract sum for the construction works being RMB83,500,000.14.
The Global Research and Development Centre is to be used by the group in its daily
operations and will serve the functions of early research and development, process
development, quality research as well as head office, among others. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.